Adiponectin signaling pathway

The **adiponectin signaling pathway** is not itself a single target molecule or receptor, but rather a cellular signaling cascade initiated by the hormone adiponectin, which is secreted by adipocytes. Adiponectin exerts its effects primarily via binding to its cell-surface receptors, **adiponectin receptor 1 (AdipoR1)** and **adiponectin receptor 2 (AdipoR2)**, as well as the accessory protein **T-cadherin**[1][2][5][7]. Upon ligand binding, these seven-transmembrane receptors activate downstream signaling pathways including **AMP-activated protein kinase (AMPK)**, **peroxisome proliferator-activated receptor alpha (PPARα)**, and p38 MAPK, resulting in enhanced insulin sensitivity, decreased gluconeogenesis, increased fatty acid oxidation, and anti-inflammatory effects[1][3][4][5][7][8][9]. Dysregulation of this pathway is associated with insulin resistance, type 2 diabetes, cardiovascular disease, and metabolic syndrome. Drugs targeting various components of the pathway, such as thiazolidinediones, indirectly enhance adiponectin levels or signaling, and synthetic agonists of adiponectin receptors (e.g., AdipoRon) have shown efficacy in preclinical models[1][2]. The pathway is notable both as a research focus and as a therapeutic target for metabolic diseases, but "adiponectin signaling pathway" itself is not a target molecule or receptor, hence not a canonical therapeutic target. For molecular drug development, the true targets are **AdipoR1 and AdipoR2**. **Summary judgment:** "Adiponectin signaling pathway" is not a specific molecule or receptor but a collection of signaling events initiated by adiponectin binding to its receptors, primarily AdipoR1, AdipoR2, and T-cadherin. Thus, it should not be considered a canonical drug target—instead, the actual receptors should be used as canonical target names[1][2][5][7].

Other names

Adiponectin pathwayAdipoR signalingAdipocytokine signaling pathway

Activation of adiponectin receptor (AdipoR1 and AdipoR2) signaling; AMPK activation; PPARα activation; Inhibition of hepatic gluconeogenesis; Promotion of fatty acid oxidation; Ceramidase activity (ceramide breakdown)[1][2][6][7]